RLMD (Relmada Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RLMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-16 | Paul Edward Kelly | COO | A | — | — |
| 2025-12-16 | Fabiana Fedeli | Director | A | — | — |
| 2025-12-16 | SERGIO TRAVERSA | Chief Executive Officer | Buy | — | — |
| 2025-12-16 | CHARLES J CASAMENTO | Director | A | — | — |
| 2025-12-16 | JOHN GLASSPOOL | Director | A | — | — |
| 2025-12-16 | Chuck Ence | CA and CO | A | — | — |
| 2025-12-16 | Maged Shenouda | Chief Financial Officer | Buy | — | — |
| 2025-11-06 | Maged Shenouda | Chief Financial Officer | Buy | — | — |
| 2025-11-06 | Paul Edward Kelly | Chief Operating Officer | Buy | — | — |
| 2025-11-06 | SERGIO TRAVERSA | Chief Executive Officer | Buy | — | — |
| 2025-11-06 | Chuck Ence | CAO and COO | Buy | — | — |
| 2025-08-28 | SERGIO TRAVERSA | Chief Executive Officer | Buy | — | — |
| 2025-06-30 | Maged Shenouda | Chief Financial Officer | A | — | — |
| 2025-06-30 | CHARLES J CASAMENTO | Director | A | — | — |
| 2025-06-30 | Paul Edward Kelly | Chief Operating Officer | A | — | — |
| 2025-06-30 | SERGIO TRAVERSA | Chief Executive Officer | A | — | — |
| 2025-06-30 | Chuck Ence | CA and CO | A | — | — |
| 2025-06-30 | JOHN GLASSPOOL | Director | A | — | — |
| 2025-06-30 | Fabiana Fedeli | Director | A | — | — |
| 2025-05-20 | Paul Edward Kelly | Chief Operating Officer | Buy | — | — |
| 2025-05-20 | Maged Shenouda | Chief Financial Officer | Buy | — | — |
| 2025-05-20 | SERGIO TRAVERSA | Chief Executive Officer | Buy | — | — |
| 2025-05-20 | Chuck Ence | CA and CO | Buy | — | — |
| 2024-10-23 | CHARLES J CASAMENTO | Director | G | — | — |
| 2024-09-11 | Paul Edward Kelly | Director | Buy | — | — |
| 2024-09-11 | CHARLES J CASAMENTO | Director | Buy | — | — |
| 2024-09-11 | Maged Shenouda | Chief Financial Officer | Buy | — | — |
| 2024-09-11 | SERGIO TRAVERSA | Chief Executive Officer | Buy | — | — |
| 2024-05-29 | Fabiana Fedeli | Director | MIXED | — | — |
| 2024-05-29 | Chuck Ence | CA and CO | MIXED | — | — |
| 2024-05-29 | SERGIO TRAVERSA | Chief Executive Officer | MIXED | — | — |
| 2024-05-29 | Maged Shenouda | Chief Financial Officer | MIXED | — | — |
| 2024-05-29 | JOHN GLASSPOOL | Director | MIXED | — | — |
| 2024-05-29 | CHARLES J CASAMENTO | Director | MIXED | — | — |
| 2024-05-29 | Paul Edward Kelly | Director | MIXED | — | — |
| 2024-01-31 | Maged Shenouda | Chief Financial Officer | Buy | — | — |
| 2024-01-31 | SERGIO TRAVERSA | Chief Executive Officer | Buy | — | — |
| 2024-01-31 | Chuck Ence | CA and CO | Buy | — | — |
| 2023-12-19 | CHARLES J CASAMENTO | Director | A | — | — |
| 2023-12-19 | SERGIO TRAVERSA | Chief Executive Officer | A | — | — |
| 2023-12-19 | Maged Shenouda | Chief Financial Officer | A | — | — |
| 2023-12-19 | JOHN GLASSPOOL | Director | A | — | — |
| 2023-12-19 | Paul Edward Kelly | Director | A | — | — |
| 2023-12-19 | Fabiana Fedeli | Director | A | — | — |
| 2023-12-19 | Chuck Ence | Chief Accounting and CO | A | — | — |
| 2023-05-30 | Fabiana Fedeli | Director | A | — | — |
| 2023-05-30 | SERGIO TRAVERSA | Chief Executive Officer | A | — | — |
| 2023-05-30 | Maged Shenouda | Chief Financial Officer | A | — | — |
| 2023-05-30 | Chuck Ence | CA and CO | A | — | — |
| 2023-05-30 | Paul Edward Kelly | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 1,300,000 | — |
| — | Chief Financial Officer | 800,000 | — |
| — | COO | 502,295 | — |
| — | CA and CO | 403,931 | — |
| — | Director | 87,500 | — |
| — | Director | 21,484 | — |
| — | Chief Medical Officer | 10,121 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RLMD quote page; the site-wide leaderboard is on the insider transactions hub.